Literature DB >> 15906363

Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers.

Hirmasa Fujita1, Susumu Sueyoshi, Toshiaki Tanaka, Yuichi Tanaka, Hiroko Sasahara, Kazuo Shirouzu, Gen Suzuki, Naofumi Hayabuchi, Hiroki Inutsuka.   

Abstract

BACKGROUND AND OBJECTIVES: Multimodal treatment is commonly adopted for patients with a T4 esophageal cancer. This trial evaluated which therapy offered a better survival: preoperative chemoradiotherapy (CRT) or postoperative CRT.
METHODS: Forty-three patients with a T4 esophageal cancer were enrolled in a prospective study in which each patient decided for themselves a treatment arm, CRT-followed-by-esophagectomy or esophagectomy-followed-by-CRT. The CRT-followed-by-esophagectomy Group received 36 Gy radiotherapy and simultaneous chemotherapy using cisplatin (CDDP) and 5-fluorouracil (5FU) preoperatively, and then 24 Gy radiotherapy and simultaneous chemotherapy using CDDP and 5FU postoperatively. The esophagectomy-followed-by-CRT Group received 60 Gy radiotherapy with two cycles of simultaneous chemotherapy using CDDP and 5FU postoperatively.
RESULTS: Of 26 patients who chose CRT-followed-by-esophagectomy, 15 (58%) underwent esophagectomy, while 7 (27%) refused surgery and 4 (15%) were inoperable. Of 17 patients who chose esophagectomy-followed-by-CRT, 14 (82%) underwent esophagectomy, while 3 (18%) underwent inspection thoracotomy. The CRT-followed-by-esophagectomy Group showed a significantly better 5-year-survival rate than the esophagectomy-followed-by-CRT Group (26% vs. 0%). Multivariate analysis demonstrated that only the response to CRT was prognostic.
CONCLUSIONS: This trial concluded that the first choice of treatment for patients with a T4 esophageal cancer was prior CRT rather than prior esophagectomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906363     DOI: 10.1002/jso.20259

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

Review 1.  Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Surg Today       Date:  2015-01-13       Impact factor: 2.549

2.  Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.

Authors:  Frederic Di Fiore; Stephane Lecleire; Olivier Rigal; Marie-Pierre Galais; Emmanuel Ben Soussan; Isabelle David; Bernard Paillot; Jacques-Henri Jacob; Pierre Michel
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

3.  Role of the modern radiotherapy in the postoperative setting for esophageal cancer.

Authors:  Gian-Carlo Mattiucci; Francesco Cellini
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

4.  Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma.

Authors:  Akihiko Okamura; Masaru Hayami; Ryotaro Kozuki; Keita Takahashi; Tasuku Toihata; Yu Imamura; Shinji Mine; Masayuki Watanabe
Journal:  Esophagus       Date:  2019-10-08       Impact factor: 4.230

5.  Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study.

Authors:  Ioannis Rouvelas; Wenyi Zeng; Mats Lindblad; Pernilla Viklund; Weimin Ye; Jesper Lagergren
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

6.  Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

Authors:  Michael B Tomblyn; Bryan H Goldman; Charles R Thomas; Jacqueline K Benedetti; Heinz-Josef Lenz; Vivek Mehta; Thaddeus Beeker; Philip J Gold; James L Abbruzzese; Charles D Blanke
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

7.  President's address of the 65th annual scientific meeting of the Japanese Association for Thoracic Surgery: challenges for advanced esophageal cancer.

Authors:  Hiromasa Fujita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-02-13

8.  Diffusely infiltrative squamous cell carcinoma of the esophagus presenting as a case with diagnostic difficulty.

Authors:  Akihiro Usui; Yasunori Akutsu; Masayuki Kano; Kiyohiko Shuto; Haruhito Sakata; Yasuo Yoneyama; Norimasa Ikeda; Takashi Oide; Hisahiro Matsubara
Journal:  Surg Today       Date:  2012-11-04       Impact factor: 2.549

9.  Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Atsuko Yamada; Toshiyuki Tanahashi; Naoki Okumura; Nobuhisa Matsuhashi; Kazuya Yamaguchi; Tatsuhiko Miyazaki
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-20       Impact factor: 3.333

10.  Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Toshiyuki Tanahashi; Naoki Okumura; Nobuhisa Matsuhashi; Kazuya Yamaguchi
Journal:  Cancer Sci       Date:  2016-05-12       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.